Europe Rapid Diagnostic Tests (RDT) Market - Industry Trends And Forecast To 2029
- Published Date: 2022-11-21
- Report ID: 144494
- Pages: 200
-
Format:
Short Description
Europe Rapid Diagnostic Tests (RDT) Market, By Product Type (Consumables and Kits, Instruments and Others), Mode (Professional Rapid Diagnostic Test Product and Over-The-Counter [OTC] Rapid Diagnostic Test Product), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic, Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy & Fertility Testing, Toxicology Testing, Others), End User (Hospital & Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes and Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe), Industry Trends and Forecast to 2029
Market Definition:
The rapid diagnostic tests, also called rapid tests, are easy-to-use tests that offer quick results, usually in less than 20 minutes. Unlike other standard and conventional tests, where the diagnosis and sampling are sent to the laboratory, the results obtained from rapid diagnostic test kits are provided at the point of care. The point of care is a place where the patients get cured. The point of care can be a providers office, a clinic, or a patients own house.
The RDTs are applicable for diagnosing and testing infectious diseases such as COVID-19, cardiology diseases, oncology, pregnancy, fertility testing, toxicology testing, drugs-of-abuse testing, cardiometabolic testing, and glucose monitoring.
The currently available technological developments in rapid diagnostics testing are the reverse transcriptase-polymerase chain reaction (RT-PCR), RT-LAMP, enzyme-linked immunosorbent assay (ELISA), and Next Generation Sequencing (NGS). The developments in the testing kits provide an effective strategy to implement robust identification and diagnosis of the pathogen. The digital approach to rapid diagnostic tests allows the research team to understand and obtain, real time-results. The use of lateral flow testing is increasing, and it has to go digital for societies to get maximum benefits from it.
Market Segmentation:
The Europe rapid diagnostic tests (RDT) market is categorized into eleven notable segments based on product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel.
On the basis of product type, the Europe rapid diagnostic tests (RDT) market is segmented into consumables and kits, instruments, and others
On the basis of mode, the Europe rapid diagnostic tests (RDT) market is segmented into professional rapid diagnostic test product, and over-the-counter [OTC] rapid diagnostic test product
On the basis of technology, the Europe rapid diagnostic tests (RDT) market is segmented into PCR-based, flow-through assays, lateral flow immunochromatographic assays, agglutination assay, microfluidics, substrate technology, and others
On the basis of modality, the Europe rapid diagnostic tests (RDT) market is segmented into laboratory based test and non-laboratory based test
On the basis of age group, the Europe rapid diagnostic tests (RDT) market is segmented into adult and pediatric
On the basis of test type, the Europe rapid diagnostic tests (RDT) market is segmented into determining confirmation, serological testing, and viral sequencing
On the basis of approach, the Europe rapid diagnostic tests (RDT) market is segmented into in-vitro diagnostic and molecular diagnostic
On the basis of specimen, the Europe rapid diagnostic tests (RDT) market is segmented into swab, blood, urine, saliva, sputum, and others
On the basis of application, the Europe rapid diagnostic tests (RDT) market is segmented into infectious disease testing, glucose monitoring, cardiology testing, oncology testing, cardiometabolic testing, drugs-of-abuse testing, pregnancy & fertility testing, toxicology testing, and others
On the basis of end user, the Europe rapid diagnostic tests (RDT) market is segmented into hospital & clinic, diagnostic laboratory, home care setting, research and academic institutes, and others
On the basis of distribution channel, the Europe rapid diagnostic tests (RDT) market is segmented into direct tender, retail sales, and others
Market Players
Some of the key market players for the Europe rapid diagnostic tests (RDT) market are listed below:
Abbott
Danaher
Cellex
Fujirebio (A Subsidiary of H.U. Group)
Access Bio
Cardinal Health
Bio-Rad Laboratories, Inc.
BD
F. Hoffmann-La Roche Ltd
bioMrieux SA
InBios International, Inc.
Luminex Corporation. A DiaSorin Company
Gnomegen LLC
QIAGEN
Quidel Corporation
Chembio Diagnostics Systems, Inc.
Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation)
Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG)
MEGAKOR DIAGNOSTIK GMBH
PerkinElmer Inc.
Sekisui Diagnostics
PTS Diagnostics
Werfen
Nova Biomedical
Trinity Biotech
TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF THE EUROPE RAPID DIAGNOSTIC TESTS (RTD) MARKET 55
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 57
2 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION 62
2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELLING 69
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 72
2.10 MARKET APPLICATION COVERAGE GRID 73
2.11 SECONDARY SOURCES 74
3 EXECUTIVE SUMMARY 75
4 PREMIUM INSIGHTS 78
5 MARKET OVERVIEW 79
5.1 DRIVERS 81
5.1.1 INCREASE IN INCIDENCE OF CHRONIC DISEASES 81
5.1.2 RISE IN GERIATRIC POPULATION 82
5.1.3 TECHNOLOGICAL ADVANCEMENTS IN THE RAPID DIAGNOSTIC TESTING 83
5.1.4 GOVERNMENT INITIATIVES FOR DIAGNOSIS OF INFECTIOUS DISEASES 83
5.1.5 RISE IN PRODUCT LAUNCHES 83
5.2 RESTRAINTS 84
5.2.1 HIGH COST ASSOCIATED WITH THE RAPID DIAGNOSTIC KITS 84
5.2.2 OPERATIONAL BARRIERS FACED WHILE CONDUCTING RAPID DIAGNOSTIC TESTS 84
5.2.3 PRODUCT RECALLS IN RAPID DIAGNOSTIC TESTS 85
5.2.4 LACK OF AWARENESS ABOUT RAPID DIAGNOSTIC TESTING 85
5.3 OPPORTUNITIES 85
5.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 85
5.3.2 RISING GOVERNMENT FUNDING 86
5.3.3 INCREASING HEALTHCARE EXPENDITURE 86
5.4 CHALLENGES 87
5.4.1 STRINGENT REGULATORY FOR MARKET APPROVAL 87
5.4.2 LACK OF TRAINING 87
6 IMPACT OF COVID-19 ON EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET 89
6.1 IMPACT ON PRICE 89
6.2 IMPACT ON SUPPLY CHAIN 89
6.3 IMPACT ON DEMAND 90
6.4 STRATEGIC INITIATIVES BY MANUFACTURERS 90
6.5 CONCLUSION 90
7 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE 92
7.1 OVERVIEW 93
7.2 CONSUMABLES AND KITS 96
7.2.1 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 97
7.2.2 IMMUNOCHROMATOGRAPHIC ASSAY 97
7.2.2.1 ANTIBODY TESTS 97
7.2.2.1.1 TOTAL ANTIBODY ELISA KIT 98
7.2.2.1.2 IGM/IGG RAPID DIAGNOSTIC TEST 98
7.2.2.1.3 IGG ELISA KIT 98
7.2.2.1.4 IGM ELISA KIT 98
7.2.2.1.5 NEUTRALIZING ANTIBODY ELISA KIT 98
7.2.2.2 ANTIGEN ELISA KITS 98
7.2.2.3 SPECIMEN COLLECTION KIT 99
7.2.3 RT-PCR ASSAY KITS 99
7.2.3.1 REVERSE TRANSCRIPTION PCR (RT-PCR) 99
7.2.3.2 QUANTITATIVE REVERSE TRANSCRIPTION PCR (RT-QPCR) 99
7.2.4 OTHERS 99
7.3 INSTRUMENTS 99
7.3.1 PORTABLE 100
7.3.2 BENCHTOP 100
7.3.3 FIXED 100
7.4 OTHERS 100
8 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE 102
8.1 OVERVIEW 103
8.2 PROFESSIONAL 106
8.3 OVER-THE-COUNTER [OTC] 107
9 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY 108
9.1 OVERVIEW 109
9.2 PCR-BASED 112
9.3 FLOW-THROUGH ASSAYS 112
9.4 LATERAL FLOW IMMUNOCHROMATOGRAPHIC ASSAYS 113
9.5 AGGLUTINATION ASSAY 113
9.6 MICROFLUIDICS 114
9.6.1 PAPER-BASED MICROFLUDICS 115
9.6.2 LUCIFERASE IMMUNOPRECIPITATION SYSTEMS (LIPS) 115
9.6.3 OTHERS 115
9.7 SUBSTRATE TECHNOLOGY 115
9.8 OTHERS 116
10 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY 117
10.1 OVERVIEW 118
10.2 LABORATORY BASED TEST 121
10.3 NON-LABORATORY BASED TEST 121
11 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP 123
11.1 OVERVIEW 124
11.2 ADULT 127
11.3 PEDIATRIC 127
12 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE 128
12.1 OVERVIEW 129
12.2 DETERMINING CONFIRMATION 132
12.2.1 RT-PCR ASSAY KITS 132
12.2.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 132
12.2.3 IMMUNOCHROMATOGRAPHIC ASSAY 133
12.2.4 OTHERS 133
12.3 SEROLOGICAL TESTING 133
12.3.1 RT-PCR ASSAY KITS 134
12.3.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 134
12.3.3 IMMUNOCHROMATOGRAPHIC ASSAY 134
12.3.4 OTHERS 134
12.4 VIRAL SEQUENCING 134
12.4.1 RT-PCR ASSAY KITS 135
12.4.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 135
12.4.3 IMMUNOCHROMATOGRAPHIC ASSAY 135
12.4.4 OTHERS 135
13 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH 136
13.1 OVERVIEW 137
13.2 IN-VITRO DIAGNOSTIC 140
13.3 MOLECULAR DIAGNOSTIC 140
14 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN 141
14.1 OVERVIEW 142
14.2 SWAB 145
14.3 BLOOD 145
14.4 URINE 146
14.5 SALIVA 146
14.6 SPUTUM 147
14.7 OTHERS 147
15 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION 149
15.1 OVERVIEW 150
15.2 INFECTIOUS DISEASE TESTING 153
15.2.1 VIRUS 154
15.2.2 BACTERIA 154
15.2.3 OTHERS 154
15.3 GLUCOSE MONITORING 154
15.4 CARDIOLOGY TESTING 155
15.5 ONCOLOGY TESTING 155
15.5.1 LUNG CANCER 156
15.5.2 BREAST CANCER 156
15.5.3 BLOOD CANCER 156
15.5.4 OTHERS 156
15.6 CARDIOMETABOLIC TESTING 156
15.7 DRUGS-OF-ABUSE TESTING 157
15.8 PREGNANCY & FERTILITY TESTING 157
15.9 TOXICOLOGY TESTING 158
15.10 OTHERS 158
16 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER 160
16.1 OVERVIEW 161
16.2 HOSPITAL & CLINIC 163
16.3 DIAGNOSTIC LABORATORY 164
16.4 HOME CARE SETTING 165
16.5 RESEARCH AND ACADEMIC INSTITUTES 165
16.6 OTHERS 166
17 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL 167
17.1 OVERVIEW 168
17.2 DIRECT TENDER 171
17.3 RETAIL SALES 171
18 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY REGION 173
18.1 EUROPE 174
18.1.1 GERMANY 186
18.1.2 FRANCE 193
18.1.3 U.K. 199
18.1.4 ITALY 205
18.1.5 SPAIN 211
18.1.6 RUSSIA 217
18.1.7 TURKEY 223
18.1.8 BELGIUM 229
18.1.9 NETHERLANDS 235
18.1.10 SWITZERLAND 242
18.1.11 REST OF EUROPE 248
19 EUROPE RAPID DIAGNOSTIC TESTS (RDT) MARKET: COMPANY LANDSCAPE 249
19.1 COMPANY SHARE ANALYSIS: EUROPE 249
20 SWOT ANALYSIS 250
21 COMPANY SHARE ANALYSIS 251
21.1 ABBOTT 251
21.1.1 COMPANY SNAPSHOT 251
21.1.2 REVENUE ANALYSIS 251
21.1.3 COMPANY SHARE ANALYSIS 252
21.1.4 PRODUCT PORTFOLIO 253
21.1.5 RECENT DEVELOPMENTS 253
21.2 F. HOFFMANN-LA ROCHE LTD 254
21.2.1 COMPANY SNAPSHOT 254
21.2.2 REVENUE ANALYSIS 254
21.2.3 COMPANY SHARE ANALYSIS 255
21.2.4 PRODUCT PORTFOLIO 256
21.2.5 RECENT DEVELOPMENTS 256
21.3 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG) 257
21.3.1 COMPANY SNAPSHOT 257
21.3.2 REVENUE ANALYSIS 257
21.3.3 COMPANY SHARE ANALYSIS 258
21.3.4 PRODUCT PORTFOLIO 259
21.3.5 RECENT DEVELOPMENTS 260
21.4 CARDINAL HEALTH 261
21.4.1 COMPANY SNAPSHOT 261
21.4.2 REVENUE ANALYSIS 261
21.4.3 COMPANY SHARE ANALYSIS 262
21.4.4 PRODUCT PORTFOLIO 263
21.4.5 RECENT DEVELOPMENT 263
21.5 QUIDEL CORPORATION 264
21.5.1 COMPANY SNAPSHOT 264
21.5.2 REVENUE ANALYSIS 264
21.5.3 COMPANY SHARE ANALYSIS 265
21.5.4 PRODUCT PORTFOLIO 266
21.5.5 RECENT DEVELOPMENTS 267
21.6 ADVACARE PHARMA 268
21.6.1 COMPANY SNAPSHOT 268
21.6.2 PRODUCT PORTFOLIO 268
21.6.3 RECENT DEVELOPMENT 268
21.7 ACCESS BIO 269
21.7.1 COMPANY SNAPSHOT 269
21.7.2 PRODUCT PORTFOLIO 269
21.7.3 RECENT DEVELOPMENTS 270
21.8 BD 271
21.8.1 COMPANY SNAPSHOT 271
21.8.2 REVENUE ANALYSIS 271
21.8.3 PRODUCT PORTFOLIO 272
21.8.4 RECENT DEVELOPMENTS 272
21.9 BIOMRIEUX SA 273
21.9.1 COMPANY SNAPSHOT 273
21.9.2 REVENUE ANALYSIS 273
21.9.3 PRODUCT PORTFOLIO 274
21.9.4 RECENT DEVELOPMENT 274
21.10 BIO-RAD LABORATORIES, INC. 275
21.10.1 COMPANY SNAPSHOT 275
21.10.2 REVENUE ANALYSIS 275
21.10.3 PRODUCT PORTFOLIO 276
21.10.4 RECENT DEVELOPMENTS 276
21.11 CELLEX 277
21.11.1 COMPANY SNAPSHOT 277
21.11.2 PRODUCT PORTFOLIO 277
21.11.3 RECENT DEVELOPMENTS 277
21.12 CHEMBIO DIAGNOSTICS SYSTEMS, INC. 278
21.12.1 COMPANY SNAPSHOT 278
21.12.2 REVENUE ANALYSIS 278
21.12.3 PRODUCT PORTFOLIO 279
21.12.4 RECENT DEVELOPMENTS 279
21.13 DANAHER 280
21.13.1 COMPANY SNAPSHOT 280
21.13.2 REVENUE ANALYSIS 280
21.13.3 PRODUCT PORTFOLIO 281
21.13.4 RECENT DEVELOPMENTS 281
21.14 FUJIREBIO (A SUBSIDIARY OF H.U. GROUP) 282
21.14.1 COMPANY SNAPSHOT 282
21.14.2 REVENUE ANALYSIS 282
21.14.3 PRODUCT PORTFOLIO 283
21.14.4 RECENT DEVELOPMENTS 283
21.15 GNOMEGAN LLC 284
21.15.1 COMPANY SNAPSHOT 284
21.15.2 PRODUCT PORTFOLIO 284
21.15.3 RECENT DEVELOPMENT 284
21.16 INBIOS INTERNATIONAL, INC 285
21.16.1 COMPANY SNAPSHOT 285
21.16.2 PRODUCT PORTFOLIO 285
21.16.3 RECENT DEVELOPMENTS 286
21.17 LAMDAGEN CORPORATION. 287
21.17.1 COMPANY SNAPSHOT 287
21.17.2 PRODUCT PORTFOLIO 287
21.17.3 RECENT DEVELOPMENTS 287
21.18 LUMINEX CORPORATION, A DIASORIN COMPANY 289
21.18.1 COMPANY SNAPSHOT 289
21.18.2 REVENUE ANALYSIS 289
21.18.3 PRODUCT PORTFOLIO 290
21.18.4 RECENT DEVELOPMENT 290
21.19 MEGAKOR DIAGNOSTIK GMBH 291
21.19.1 COMPANY SNAPSHOT 291
21.19.2 PRODUCT PORTFOLIO 291
21.19.3 RECENT DEVELOPMENT 291
21.20 NOVA BIOMEDICAL 292
21.20.1 COMPANY SNAPSHOT 292
21.20.2 PRODUCT PORTFOLIO 292
21.20.3 RECENT DEVELOPMENTS 293
21.21 PERKIN ELMER INC. 294
21.21.1 COMPANY SNAPSHOT 294
21.21.2 REVENUE ANALYSIS 294
21.21.3 PRODUCT PORTFOLIO 295
21.21.4 RECENT DEVELOPMENTS 296
21.22 PTS DIAGNOSTICS 297
21.22.1 COMPANY SNAPSHOT 297
21.22.2 PRODUCT PORTFOLIO 297
21.22.3 RECENT DEVELOPMENTS 298
21.23 QIAGEN 299
21.23.1 COMPANY SNAPSHOT 299
21.23.2 REVENUE ANALYSIS 299
21.23.3 PRODUCT PORTFOLIO 300
21.23.4 RECENT DEVELOPMENT 300
21.24 SEKISUI DIAGNOSTICS 301
21.24.1 COMPANY SNAPSHOT 301
21.24.2 PRODUCT PORTFOLIO 301
21.24.3 RECENT DEVELOPMENTS 302
21.25 SYSMEX EUROPE GMBH (A SUBSIDIARY OF SYSMEX CORPORATION) 303
21.25.1 COMPANY SNAPSHOT 303
21.25.2 REVENUE ANALYSIS 303
21.25.3 PRODUCT PORTFOLIO 304
21.25.4 RECENT DEVELOPMENTS 304
21.26 TRINITY BIOTECH 305
21.26.1 COMPANY SNAPSHOT 305
21.26.2 REVENUE ANALYSIS 305
21.26.3 PRODUCT PORTFOLIO 306
21.26.4 RECENT DEVELOPMENT 306
21.27 WERFEN 307
21.27.1 COMPANY SNAPSHOT 307
21.27.2 PRODUCT PORTFOLIO 307
21.27.3 RECENT DEVELOPMENT 307
22 QUESTIONNAIRE 308
23 RELATED REPORTS 313
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
